Category: W.L. Gore & AssociatesSyndicate content

Gore lands CE Mark for Viabahn vascular device

December 11, 2014 by Val Kennedy

Gore Medical receives CE Mark approval in the European Union for its Viabahn vascular device for the treatment of obstructed peripheral veins in hemodialysis patients.

Gore lands CE Mark for Viabahn vascular device

Gore Medical said it received CE Mark approval for its Viabahn vascular device for the treatment of obstructed peripheral veins in hemodialysis patients.

The Flagstaff, Ariz.-based company said the approval covers the treatment of obstructed peripheral veins, excluding the venae cavae and pulmonary veins.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA releases final recs on legal exemptions for customized medical devices | Regulatory news for the week of September 29, 2014

September 30, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: FDA guides on custom devices; FDA approves Gore's Viabahn for peripheral stent repair; Alcon wins date with FDA panel for AcrySof lens; FDA seeks public input on medtech hacking; ReFlow Medical wins CE Mark for crossing catheters;

FDA guides on custom devices

September 25, 2014 by Alexander Soule

FDA guides on custom devices

FDA approves Gore's Viabahn for peripheral stent repair

September 26, 2014 by Alex Soule

The FDA adds an indication to its approval of W.L. Gore's Viabahn peripheral stent graft in treating failed bare-metal stents.

FDA approves Gore's Viabahn for peripheral stent repair

W.L. Gore & Assoc. said the FDA granted pre-market approval for a new indication for its Viabahn endoprosthesis, to treat failed bare-metal stents in the peripheral vasculature.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Appeals court upholds win for Gore in patent war with STJ | Medtech legal news for the week of June 16, 2014

June 16, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Appeals court upholds Gore win over St. Jude Medical; Independent legal panel rejects Infuse allegations in Medtronic shareholder suits; Judge dismisses Anulex from Xclose off-label lawsuit; Appeals court upholds Abiomed win in shareholder's class action; Convicted ex-Heart Tronics CEO won't get a retrial, judge rules.

Appeals court upholds Gore win over St. Jude Medical

June 9, 2014 by Brad Perriello

Appeals court upholds Gore win over St. Jude Medical

Appeals court upholds Gore win over St. Jude Medical

June 9, 2014 by Brad Perriello

A federal appeals court upholds W.L. Gore & Assoc.'s win over St. Jude Medical in their patent spat over heart defect repair technology.

Appeals court upholds Gore win over St. Jude Medical

A federal appeals court today upheld a win for W.L. Gore & Assoc. in a patent war with St. Jude Medical (NYSE:STJ) over heart defect repair technology.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Gore's Viabahn stent graft bests angioplasty, study finds

February 20, 2014 by Arezu Sarvestani

W.L. Gore's newly approved drug-coated Viabahn stent graft beat the current standard of care in treating patients with stenoses or thrombotic occlusions, according to the REVISE clinical study findings.

Gore's Viabahn stent graft bests angioplasty, study finds

Arizona medical device maker W.L. Gore & Assoc. teased positive results from its REVISE clinical trial, promising to release additional findings during the American Society of Diagnostic & Interventional Nephrology meeting in Phoenix this week.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Legal win, buyouts boost Bard's bottom line

February 3, 2014 by Brian Johnson

C.R. Bard's 4th-quarter bottom line gets a significant boost from a nearly $900 million legal payment from rival W.L. Gore and the more than $200 million gain from selling its electrophysiology business to Boston Scientific.

A nearly $900 million award from W.L. Gore boosted C.R. Bard's bottom line in Q4 as sales inch up 3% in 2013: Officials announce $500 million share buyback plan.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp